SANTA MONICA, Calif.–(BUSINESS WIRE)–FIGS, Inc. (NYSE: FIGS), the direct-to-consumer healthcare apparel and lifestyle brand, today announced it will release its second quarter 2022 financial results on Thursday, August 4, 2022, after U.S. markets close. FIGS management will host a conference call that day at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial … [Read more…]
LifeWorks Mental Health IndexTM reveals Americans whose employers supported their mental health during the pandemic have highest mental health scores CHICAGO–(BUSINESS WIRE)–LifeWorks, a leading provider of digital and in-person total wellbeing solutions, today released its monthly Mental Health IndexTM revealing 63 percent of Americans believe people with mental health conditions are treated differently. Additionally, the … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Biosensors Market: Focus on Drug Discovery and Development – Distribution by Type of Biosensor, Type of End User and Key Geographies – Industry Trends and Global Forecasts, 2022-2035” report has been added to ResearchAndMarkets.com’s offering. At present, various types of biosensors, including optical biosensors, electrochemical biosensors, thermal biosensors and others, are being deployed … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Oncology Information System Market by Application (Medical, Radiation, Surgical Oncology), by Software (Patient Information System, TPS, RIS, PACS, Services), End User (Hospitals, Cancer Care Centers, Government Institution) and by Region – Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering. The global oncology information systems market size is estimated to be USD … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “In Vitro Diagnostic Market Brief Update” report has been added to ResearchAndMarkets.com’s offering. What Major Trends are Affecting the Market Diagnostic test products have never been more important. This report is an update of the market for in vitro diagnostics products from the analysts to reflect the latest information as of Q4 2021. … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Colorectal Cancer Screening Tests Market Analysis by Screening Test (Flexible Sigmoidoscopy, Stool-Based Tests, CT Colonography, Colonoscopy), by End User (Independent Diagnostic Labs, Hospitals), and by Region – Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering. The global colorectal cancer screening tests market size is estimated to be USD 12,994 million in … [Read more…]
NeuroFront receives an exclusive option for an exclusive license to develop, commercialize and manufacture NRD.E1, Novaremed’s first-in-class, non-opioid investigational drug for the treatment of chronic neuropathic pain in Greater China and Singapore Novaremed is entitled to receive a total of over USD 130 million in option and exercise fees as well as development, regulatory and … [Read more…]
AUSTIN, Texas & PARIS–(BUSINESS WIRE)–DentalMonitoring has launched a breakthrough service for dental professionals and industry partners: the DM Intelligent Platform is now the only digital workflow which can interface and integrate with all dental digital solutions available on the market today. This industry-first accomplishment reinforces DentalMonitoring’s vision of making dentistry smarter, helping improve clinical outcomes … [Read more…]
IPH6401/SAR’514 is a BCMA-targeting NK cell engager using Sanofi’s proprietary CROSSODILE® multi-functional platform. It was developed jointly and benefits from the dual NK targeting of Innate’s ANKETTM proprietary platform Selection of IPH6401/SAR’514 triggers a €3M milestone payment to Innate MARSEILLE, France–(BUSINESS WIRE)–Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) … [Read more…]
– Peking Union Medical College Hospital Primary Clinical Trial Site BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–CANbridge Pharmaceuticals Inc. (HKEX:1228), a China and US-based global biopharmaceutical company committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, announced that the first patient has been dosed in the CAN103 Phase 1/2 trial in … [Read more…]
